December 10, 2005
Tercica Announces Submission Of Marketing Application

Tercica announced submission of Marketing Application to the European Agency For Evaluation of Medicinal Products, for the right to sell Increlex in the European Union.

The FDA approved the use of Increlex ™ last August. It is primarily for use in people suffering from Primary Insulin Growth Factor Deficiency (IGFD) or Growth Hormone Gene Deletion.

Increlex ™ is the synthetic version of the hormone IGF, which is released in response to stimulation by Growth Hormone. By giving Increlex™ to children deficient in IGF, the, they should be able to increase in height.